Larimar Therapeutics shares surged 35.6% in pre-market trading after the company announced that its treatment for a neurological disease had received “Breakthrough Therapy” designation from the U.S. Food and Drug Administration (FDA).

Larimar Therapeutics shares surged 35.6% in pre-market trading after the company announced that its treatment for a neurological disease had received “Breakthrough Therapy” designation from the U.S. Food and Drug Administration (FDA).

老虎证券2026/02/24 13:55

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

This designation usually means that the drug has shown significant advantages in early clinical studies and is expected to accelerate its subsequent development and review process.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Larimar Therapeutics shares surged 35.6% in pre-market trading after the company announced that its treatment for a neurological disease had received “Breakthrough Therapy” designation from the U.S. Food and Drug Administration (FDA).

You may also like

Trending news

Crypto prices